Sirtex is a global life-sciences company that markets SIR-Spheres® Y-90 resin microspheres, a targeted radiation therapy for patients with inoperable primary or secondary (metastatic) liver tumors. Sirtex has supplied over 86,000 doses of SIR-Spheres Y-90 resin microspheres to 1,160 centers in over 40 countries worldwide. Sirtex (SRX) is listed on the Australian Securities Exchange.
Our significant investments in people, research, product development, marketing, clinical studies and other sales growth initiatives has created a foundation for a global business that will continue to create value over the coming years.
The vision of Sirtex is that cancer will no longer be a terminal disease …but a disease that patients can successfully live with.
The global Sirtex team over the past few years has grown significantly and we now have over 266 employees located in 20 countries.
The Global Head Office of Sirtex is in Sydney, Australia, the Americas Regional Headquarter is located in Boston, USA and the European, Middle East, African (EMEA) Regional Headquarter is located in Bonn, Germany.